Skip to main content
Clinical Trials/NCT02092740
NCT02092740
Completed
Not Applicable

Retrospective Analysis of Testicular Cancer Patients With Histopathological Analysis or Urological Treatment at the University Magdeburg 1960-2012.

University of Magdeburg1 site in 1 country2,000 target enrollmentNovember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Testicular Cancer
Sponsor
University of Magdeburg
Enrollment
2000
Locations
1
Primary Endpoint
Overall survival (OS)
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Retrospective analysis of treatment outcome and side effects of testicular cancer patients that had been diagnosed at the University Magdeburg from 1960 until 2012.

Detailed Description

Creating an ACCESS Windows form based Data Registry for testicular cancer patients. Relevant data for testicular cancer patients based on EAU-guidelines 2013 and EORTC/RTOG, Lent-SOMA, CTC. All testicular cancer patients who had been histopathologically diagnosed al the Institute of Pathology at the University Magdeburg. About 2000 patients from 1960 until 2012. Postgraduate students collecting data requesting hospital documents, cancer registry of Sachsen-Anhalt, family practitioners and urologists as well as patients. Statistically Analysis with ACCESS and IBM SPSS statistics.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
December 2012
Last Updated
12 years ago
Study Type
Observational
Sex
Male

Investigators

Sponsor
University of Magdeburg
Responsible Party
Principal Investigator
Principal Investigator

Johann J. Wendler, MD

Dr. med. Johann Jakob Wendler

University of Magdeburg

Eligibility Criteria

Inclusion Criteria

  • testicular cancer histopathologically diagnosed at the University Magdeburg Germany

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Overall survival (OS)

Time Frame: Up to 52 years.

Overall survival (OS).

Secondary Outcomes

  • Disease-specific survival.(Up to 52 years.)
  • Chronic side effects of testicular-cancer-specific radiation therapies.(Up to 52 years.)
  • Chronic side effects of testicular-cancer-specific surgical therapies.(Up to 52 years.)
  • Secondary Malignoma(Up to 52 years.)
  • Chronic side effects of testicular-cancer-specific chemotherapies.(Up to 52 years.)
  • Cause of death.(Up to 52 years.)
  • Progressive-free survival (PFS).(Up to 52 years.)
  • Relapse-free survival (RLS).(Up to 52 years.)
  • Quality of Life (QoL).(Current situation.)

Study Sites (1)

Loading locations...

Similar Trials